736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies

Bibliographic Details
Title: 736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies
Authors: Mario Sznol, Harriet Kluger, Igor Puzanov, Gerald S Falchook, Ryan Sullivan, Matthew H Taylor, Justin C Moser, Aaron M Ring, Virginia E Paton, David Chonzi, Brage Garofalo, Mark Sonnemann, Hirdesh Uppal, Jeremy Barton, Beatrice Y McQueen
Source: Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Publisher Information: BMJ Publishing Group, 2023.
Publication Year: 2023
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2051-1426
Relation: https://doaj.org/toc/2051-1426
DOI: 10.1136/jitc-2023-SITC2023.0736
Access URL: https://doaj.org/article/c9d6a589d3ec4c688bdb430c28cf8a3d
Accession Number: edsdoj.9d6a589d3ec4c688bdb430c28cf8a3d
Database: Directory of Open Access Journals
More Details
ISSN:20511426
DOI:10.1136/jitc-2023-SITC2023.0736
Published in:Journal for ImmunoTherapy of Cancer
Language:English